Romatoid Artritte Göz Bulguları: Retrospektif Çalışma

Abstract

Amaç:Bu çalışmanın amacı Romatoid Artrit (RA)hastalarında eşlik eden göz bulgularını , sıklığını saptamak ve komplikasyonları incelemektir. Yöntem:1Mart 2017 ile 1 Mart 2022 tarihleri arasında göz kliniği ile konsülte edilmiş,Romatoid Artrit hastalarının tıbbi kayıtları retrospektif olarak incelendi.Demografik özellikler, göz muayene bulguları ve saptanan göz hastalıkları not edildi. Bulgular: Göz Kliniği ile konsülte edilen 23840 Romatoid Artrit ve ilişkili tanı almış hasta kaydı incelendi.Bu hasta kayıtlarından özellikle seropozitif Romatoid Artrit tanısı almış 2691 hasta çalışma kapsamında detaylı değerlendirildi.Kayıtlerden elde edilen oftalmolojik muayene bulguları incelendi.Hastaların özellikle ,ön segment biyomikroskopisi, Schirmer testi, gözyaşı kırılma süresi (BUT) ve gözdibi muayeneleri değerlendirildi. Hastaların 2067’si kadın 624’ü erkek idi ve yaş ortalaması incelendiğinde; 1795 hasta (1374 kadın,421 erkek) ile en sık 41-65 yaş arası hasta mevcuttu. Oküler tutulumun en sık görülen belirtisi gözyaşı eksikliği (kuru göz) iken, hastaların %4.6'sında episklerit,%1,37'sinde sklerit saptandı. İncelenen hastalar arasında posterior veya nekrotizan skleritli hasta yoktu. Ayrıca hastalarımızda korneanın arka skleriti, skleromalazisi veya retinal vascülit de saptanmadı. Sonuç: Romatoid Artrit eklem dışı bulgularla da seyredebilen ve hatta ilk bulgu olarak da ortaya çıkabilen bir hastalıktır.Hastalığa küçümsenmeyecek oranda göz bulgusu eşlik edebilir.Doğru bakış açısı ile hastalık prognozunu da etkileyebilir

Keywords

• Romatoid artrit
• göz
• sklerit
• episklerit

Ocular Findings in Rheumatoid Arthritis: Retrospective Study

Abstract

Objective: The aim of this study is to determine the accompanying ocular findings, frequency and to examine the complications in Rheumatoid Arthritis (RA) patients. Method: Medical records of Rheumatoid Arthritis patients who were consulted with the eye clinic between 2017 and 2022, were retrospectively reviewed. Demographic features, eye examination findings, and detected eye diseases were noted. Results: The records of 23840 Rheumatoid Arthritis and related patients who were consulted with the Eye Clinic were reviewed. From these patient records, 2691 patients, who were especially diagnosed with seropositive Rheumatoid Arthritis, were evaluated in detail within the scope of the study. Ophthalmological examination findings obtained from the records were examined. In particular, anterior segment biomicroscopy, Schirmer test, tear break-up time (BUT) and fundus examination was evaluated. 2067 of the patients were female and 624 were male. And the mean age was examined. When the average age is examined; patients aged 41-65 years were the most common (1795 patients (1374 women, 421 men)). The most common sign of ocular involvement was a dry eye(%25.97). Less frequently, episcleritis was found in 4.57% of patients, and scleritis was found in 1.37%. There were no patients with posterior or necrotizing scleritis among the patients examined. In addition, posterior scleritis of the cornea, scleromalacia, or retinal vasculitis were not detected in our patients. Conclusion: Rheumatoid Arthritis is a disease that can progress with extra-articular findings and may even appear as the first finding. Ocular findings may accompany the disease at a considerable rate. It can also affect the prognosis of the disease with the right perspective.

Keywords

• Rheumatoid artrhritis
• eye
• scleritis
• episcleritis

References

1. Referans1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-86.
2. Referans2. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003 Aug;62(8):722-7.
3. Referans3. Mease PJ, Bhutani MK, Hass S, Yi E, Hur P, Kim N. Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review. Rheumatol Ther. 2022 Apr;9(2):331-378.
4. Referans4. Abd-Allah NM, Hassan AA, Omar G, Hamdy M, Abdelaziz STA, Abd El Hamid WM, et al. Dry eye in rheumatoid arthritis: relation to disease activity. Immunol Med. 2020 Jun;43(2):92-97.
5. Referans5. Ma W, Wang G, Li X, Wu H, Liu Z, Dong N, et al. Study of Factors Influencing Dry Eye in Rheumatoid Arthritis. J Ophthalmol. 2020 Aug 8;2020:5768679.
6. Referans6. Whitson WE, Krachmer JH. Adult rheumatoid arthritis. In: Gold DH, Weingeist TA, editors. The eye in systemic disease. Philadelphia: JB Lippincott; 1990. pp. 127–208
7. Referans7. Sims J. Scleritis: presentations, disease associations and management. Postgrad Med J. 2012 Dec;88(1046):713-8.
8. Referans8. Wieringa WG, Wieringa JE, ten Dam-van Loon NH, Los LI. Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology. 2013 Feb;120(2):379-86.

9. Referans9. Nishio Y, Taniguchi H, Takeda A, Hori J. Immunopathological Analysis of a Mouse Model of Arthritis-Associated Scleritis and Implications for Molecular Targeted Therapy for Severe Scleritis. Int J Mol Sci. 2021 Dec 29;23(1):341.
10. Referans10. Bhamra MS, Gondal I, Amarnani A, Betesh S, Zhyvotovska A, Scott W, Rodriguez-Alvarez M, Lazzaro DR, McFarlane IM. Ocular Manifestations of Rheumatoid Arthritis: Implications of Recent Clinical Trials. Int J Clin Res Trials. 2019;4(2):139.
11. Referans11. Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012 Jan;119(1):43-50.
12. Referans12. Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P. Scleritis: Immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res. 2013 Jul;35:44-62.
13. Referans13. Watson P, Romano A. The impact of new methods of investigation and treatment on the understanding of the pathology of scleral inflammation. Eye (Lond). 2014 Aug;28(8):915-30.
14. Referans14. Turhanoğlu D, Erman Yağız A, Üstün N, Ayhan Tuzcu E, Güler H. Romatoid artrit ve ankilozan spondilit hastalarında göz bulgularının değerlendirilmesi. Harran Üniversitesi Tıp Fakültesi Dergisi. 2014; 11(1): 28-33.
15. Referans15. Galor A, Jabs DA, Leder HA, Kedhar SR, Dunn JP, Peters GB 3rd, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008 Oct;115(10):1826-32.
16. Referans16. Karabulut G, Özbalkan Aşlar Z. Romatoid artrit tedavi prensipleri: Neye geçiş yapalım? Ege Journal of Medicine 2021; 60: Ek Sayı /Supplement 42-43.
17. Referans17. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020 Feb;72(2):149-162. doi: 10.1002/acr.24131. Epub 2020 Jan 6. Erratum in: Arthritis Care Res (Hoboken). 2021 May;73(5):764.
18. Referans18. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007 Jul;125(7):895-900.
19. Referans19. Sota J, Girolamo MM, Frediani B, Tosi GM, Cantarini L, Fabiani C. Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review. Ophthalmol Ther. 2021 Dec;10(4):777-813.
20. Referans20. Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, et al. FAST Research Group. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. JAMA. 2019 Sep 10;322(10):936-945.
21. Referans21. Ragam A, Kolomeyer AM, Fang C, Xu Y, Chu DS. Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors. Ocul Immunol Inflamm. 2014 Dec;22(6):469-77.
22. Referans22. Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, et al. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2021 Sep;105(9):1256-1262.